drugset / Trial / NCT07228247
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.
Timeline
- Start
- 2025-12-16
- Primary completion
- 2028-11-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HMPL-A251 | Unknown | — | Intravenous |
Indications
No indication recorded.